Taking into account the above and the data obtained in our work, Gal-3 is a promising biomarker that stratifies patients at risk of CV events including HF in T2DM patients, as emphasized by other authors [6], and requires further study. The gene discussed is LGALS3; the disease is type 2 diabetes mellitus.